Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 11:00 AM ET
Kyverna Therapeutics announced publication of registrational miv-cel data in stiff person syndrome in JAMA Neurology.
NASDAQ: $KYTXBiotech · Autoimmune cell therapyBLA, cell-therapy safety and dilution risk
KYTX Stock Hub: Kyverna News, Miv-cel and Autoimmune CAR-T
Kyverna targets completion of its rolling SPS BLA in Q4 2026, with a potential launch in 2027 subject to approval. KYSA-8 one-year data cover 26 treated patients; gMG longer-term data come from a separate seven-patient Phase 2 cohort. Latest published financials are Q2 2026, with $199.427M June cash and marketable securities. SPS and gMG longer-term data · September 24, 2026 Q2 2026 Form 10-Q · August 11 Corporate presentation · October 2026
Research Library · Biotech
Kyverna: Miv-cel, SPS Durability and the Autoimmune CAR-T Path
SPS durability, gMG confirmation and a rolling BLA still in progress · November 12, 2026
Next catalyst · Announced investor presentation
November 19, 2026 · Jefferies Global Healthcare Conference
Management is scheduled to present in London at 10:00 GMT, equivalent to 05:00 in New York. This is an investor event, without a promise of new clinical data or BLA acceptance. Jefferies conference announcement · November 5, 2026
The November 9 journal publication concerns the earlier KYSA-8 primary analysis; one-year durability was reported in September and presented in October. The next regulatory window is completion of the rolling SPS BLA in Q4, not a confirmed FDA decision date. KYSA-8 publication announcement · November 9, 2026 SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026
KYTX stock data: financial position and capital
REFERENCE CLOSE
$5.12
November 11 regular session
COMMON-STOCK VALUE
$316.638M
Calculated using August 3 common shares
CASH + MARKETABLES
$199.427M
June 30 · excludes restricted cash
Q2 NET LOSS
$38.319M
Three months ended June 30
OPERATING CASH USED
$81.903M
Six months ended June 30
COMMON SHARES
61.843M
August 3 cover-page count
ATM CAPACITY LEFT
$96.3M
June 30 · financing capacity, not cash
TERM LOAN CARRYING
$24.883M
June 30 · $25M nominal principal
Resources equal $31.806M cash and equivalents plus $167.621M marketable securities. Restricted cash of $0.551M is separate. Oxford’s up-to-$150M facility had $25M principal drawn; later tranches have conditions or lender discretion. The company’s runway into 2028 includes financing assumptions. Q2 2026 Form 10-Q · August 11 Q2 financial results and pipeline · August 11, 2026
KYTX stock: durable SPS data with regulatory and treatment risks
Miv-cel is not approved. In KYSA-8, CRS occurred in 24/26 patients, all grade 1 or 2; ICANS occurred in 3/26, all grade 1. Grade 3/4 neutropenia affected five patients, and three had related serious adverse events that resolved. No high-grade CRS or ICANS does not mean no adverse events. Corporate presentation · October 2026
▲ The constructive case
The single-dose SPS study met its primary endpoint and maintained mobility and disability improvements through one year, with 24/26 patients remaining free of chronic SPS immunotherapies. A focused launch strategy and gMG development offer additional paths if regulatory and clinical requirements are met. SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026
▼ The cautious case
KYSA-8 was a 26-patient single-arm study; the gMG Phase 2 cohort had seven patients. Longer observation and controlled confirmation remain important. Cell-therapy logistics, preconditioning, safety, cash consumption and an available ATM all affect the path from promising data to shareholder value. Corporate presentation · October 2026 Q2 2026 Form 10-Q · August 11
Latest KYTX news
Nov 9, 2026
Kyverna Publishes Registrational Miv-cel Data in Stiff Person Syndrome in JAMA Neurology
Kyverna Therapeutics published the primary analysis of its registrational KYSA-8 trial of miv-cel in stiff person syndrome in JAMA Neurology. The 26 patients received a single dose and showed statistically significant improvements across all primary and secondary endpoints at 16 weeks. Of the 12 patients who required walking aid at baseline, 67% no longer needed walking assistance at 16 weeks. No high-grade CRS or ICANS and no cases of IEC-HS were reported.
KYTX stock catalysts: rolling BLA, Jefferies and gMG enrollment
- November 19, 2026 — Jefferies presentation, 10:00 GMT / 05:00 New York. Jefferies conference announcement · November 5, 2026 Announced investor event
- Q4 2026 — Completion of the rolling miv-cel BLA in SPS. Corporate presentation · October 2026 SPS and gMG longer-term data · September 24, 2026 Company filing target; no exact day
- Early 2027 — Progressive-MS development strategy update. Progressive MS investigator-study update · October 23, 2026 Corporate presentation · October 2026 Company forecast
- Mid-2027 — Completion of enrollment in the Phase 3 gMG portion of KYSA-6. SPS and gMG longer-term data · September 24, 2026 Company enrollment target
- 2027 — Potential first SPS commercial launch, subject to approval. Corporate presentation · October 2026 Conditional company ambition
- January–September 2027 — Several registry primary-completion estimates, including ANCA, CARTIMMUNE, MS and gMG. NCT06590545 · trial registry NCT06152172 · trial registry NCT06384976 · trial registry NCT06193889 · trial registry Operational estimates, not promised readouts
The SPS 12-month and gMG longer-term updates were released September 24; October conference presentations and November publication are past. No FDA acceptance or PDUFA date had been announced as of November 12, 2026. Registry phase and enrollment can describe a broader program than an individual published cohort. SPS and gMG longer-term data · September 24, 2026 KYSA-8 publication announcement · November 9, 2026 Kyverna company news
Miv-cel in SPS: one-year durability and the safety denominator
KYSA-8 treated 26 adults in a single-arm study. Median T25FW improvement was 46% at week 16 and 49% at one year. Clinically meaningful improvement occurred in 21/26 and 20/26, respectively; 24/26 remained off chronic immunotherapies at one year. SPS and gMG longer-term data · September 24, 2026 Corporate presentation · October 2026
Grade 3/4 neutropenia occurred in 5/26 and related serious adverse events in 3/26. Low-grade CRS and ICANS occurred despite the absence of high-grade cases. The November publication reports the primary analysis, distinct from the later one-year dataset. Corporate presentation · October 2026 KYSA-8 publication announcement · November 9, 2026
gMG and progressive MS: early cohorts versus confirmation
All seven gMG Phase 2 patients improved meaningfully at week 24; only five had reached at least one year at the June cutoff. Six of seven remained off immunosuppressants at last follow-up. The randomized Phase 3 portion is a separate confirmatory step, with enrollment targeted for mid-2027. SPS and gMG longer-term data · September 24, 2026
The October MS update concerned six treated investigator-study patients, with efficacy available for five. These small, uncontrolled data support further development rather than establish comparative disease modification. Progressive MS investigator-study update · October 23, 2026
Merlintrader Health Score · KYTX
3.25out of 5
Weighted calculation: 3.0 × 30% + 4.0 × 30% + 2.5 × 20% + 3.0 × 10% + 3.5 × 10% = 3.25 out of 5. Editorial assessment dated November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of approval.
KYTX red flags
- Rolling BLA completion, FDA acceptance, priority review and approval are distinct milestones. Q2 financial results and pipeline · August 11, 2026
- SPS evidence is single-arm; early gMG and MS cohorts are small and have unequal follow-up. SPS and gMG longer-term data · September 24, 2026 Progressive MS investigator-study update · October 23, 2026
- Low-grade CRS and ICANS, severe neutropenia and serious related events occurred in SPS. Corporate presentation · October 2026
- The company remains precommercial and used $81.903M operating cash in six months. Q2 2026 Form 10-Q · August 11
- Options, RSUs/PRSUs and remaining ATM capacity expose ordinary holders to dilution. Q2 2026 Form 10-Q · August 11
- Oxford funding has tranche conditions and covenants; $150M facility maximum is not cash already received. Q2 2026 Form 10-Q · August 11
KYTX Stock FAQ: Kyverna Questions Answered
What is the next KYTX stock catalyst for Kyverna?
As of November 12, 2026, Kyverna’s next announced investor event is Jefferies on November 19 at 10:00 GMT / 05:00 New York. Completion of the rolling SPS BLA remains targeted for Q4 2026, without an announced exact day. Jefferies conference announcement · November 5, 2026 Corporate presentation · October 2026
Is Kyverna miv-cel FDA-approved, and does KYTX have a PDUFA date?
As of November 12, 2026, miv-cel remains investigational and Kyverna had not announced BLA acceptance or a PDUFA date. The company targets completion of its rolling SPS application in Q4. RMAT designation and a request for priority review do not constitute approval. Q2 financial results and pipeline · August 11, 2026 Corporate presentation · October 2026 Kyverna company news
How much cash does Kyverna have for KYTX development?
At June 30, 2026, Kyverna had $199.427M in cash, equivalents and marketable securities, excluding $0.551M restricted cash. Its forecast operating runway into 2028 includes financing assumptions and available loan capacity; it is not a guarantee based solely on the cash balance. Q2 2026 Form 10-Q · August 11 Q2 financial results and pipeline · August 11, 2026
What are the main KYTX share dilution risks for Kyverna holders?
At June 30, 2026, Kyverna had 10,590,212 options and 1,686,922 unvested RSUs/PRSUs besides ordinary shares. Its ATM had $96.3M capacity remaining, with another $200M unallocated under the shelf. Registered financing capacity is not cash received. Q2 2026 Form 10-Q · August 11
What are the latest Kyverna earnings for KYTX stock?
As of November 12, 2026, Kyverna had not announced Q3 2026 results. Latest published Q2 results included a $38.319M net loss, $199.427M June cash and marketable securities, and $81.903M operating cash use for the first six months. Q2 2026 Form 10-Q · August 11 Kyverna company news
What does Kyverna Therapeutics do with miv-cel for KYTX?
As of November 12, 2026, Kyverna develops miv-cel, an autologous CD19 CAR-T therapy for B-cell-driven autoimmune diseases. Its prioritized neurologic programs include stiff person syndrome, generalized myasthenia gravis and progressive multiple sclerosis. Miv-cel is intended as a single infusion after preconditioning and remains investigational. Corporate presentation · October 2026
What did Kyverna report for KYTX miv-cel in stiff person syndrome?
On September 24, 2026, Kyverna reported one-year data in 26 treated KYSA-8 patients, including 49% median T25FW improvement and 92% remaining free of chronic SPS immunotherapies. The study was single-arm. The November 9 publication concerns the earlier primary analysis, not a new randomized dataset. SPS and gMG longer-term data · September 24, 2026 KYSA-8 publication announcement · November 9, 2026
What are the clinical safety risks of Kyverna miv-cel for KYTX?
In the October 2026 presentation, KYSA-8 safety included CRS in 24/26 patients and ICANS in 3/26, all low grade. Five had grade 3/4 neutropenia and three had related serious adverse events that resolved. The absence of high-grade CRS or ICANS does not eliminate other risks. Corporate presentation · October 2026
Primary sources
- Q2 2026 Form 10-Q · August 11
- SPS and gMG longer-term data · September 24, 2026
- Corporate presentation · October 2026
- Full one-year KYSA-8 data · October 21, 2026
- KYSA-8 publication announcement · November 9, 2026
- Jefferies conference announcement · November 5, 2026
- NCT06588491 · trial registry
- NCT06193889 · trial registry
- Progressive MS investigator-study update · October 23, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $KYTX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
